Current and historical daily PE Ratio for PPHOF (
Spexis AG
) from 2019 to May 13 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Spexis AG stock (PPHOF) PE ratio as of May 13 2024 is 0.
More Details
Spexis AG (PPHOF) PE Ratio (TTM) Chart
Spexis AG (PPHOF) PE Ratio (TTM) Historical Data
View and export this data going back to 2019. Start your Free Trial
Total 648
- 1
- 2
- 3
- 4
- 5
- 6
- 8
| Spexis AG PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-13 | At Loss | 2023-07-05 | At Loss |
| 2023-09-06 | At Loss | 2023-06-30 | At Loss |
| 2023-09-05 | At Loss | 2023-06-29 | At Loss |
| 2023-09-01 | At Loss | 2023-06-28 | At Loss |
| 2023-08-31 | At Loss | 2023-06-27 | At Loss |
| 2023-08-30 | At Loss | 2023-06-26 | At Loss |
| 2023-08-29 | At Loss | 2023-06-23 | At Loss |
| 2023-08-28 | At Loss | 2023-06-22 | At Loss |
| 2023-08-25 | At Loss | 2023-06-21 | At Loss |
| 2023-08-24 | At Loss | 2023-06-20 | At Loss |
| 2023-08-23 | At Loss | 2023-06-16 | At Loss |
| 2023-08-22 | At Loss | 2023-06-15 | At Loss |
| 2023-08-21 | At Loss | 2023-06-14 | At Loss |
| 2023-08-18 | At Loss | 2023-06-13 | At Loss |
| 2023-08-17 | At Loss | 2023-06-12 | At Loss |
| 2023-08-16 | At Loss | 2023-06-09 | At Loss |
| 2023-08-15 | At Loss | 2023-06-08 | At Loss |
| 2023-08-14 | At Loss | 2023-06-07 | At Loss |
| 2023-08-11 | At Loss | 2023-06-06 | At Loss |
| 2023-08-10 | At Loss | 2023-06-05 | At Loss |
| 2023-08-09 | At Loss | 2023-06-02 | At Loss |
| 2023-08-08 | At Loss | 2023-06-01 | At Loss |
| 2023-08-07 | At Loss | 2023-05-31 | At Loss |
| 2023-08-04 | At Loss | 2023-05-30 | At Loss |
| 2023-08-03 | At Loss | 2023-05-26 | At Loss |
| 2023-08-02 | At Loss | 2023-05-25 | At Loss |
| 2023-08-01 | At Loss | 2023-05-24 | At Loss |
| 2023-07-31 | At Loss | 2023-05-23 | At Loss |
| 2023-07-28 | At Loss | 2023-05-22 | At Loss |
| 2023-07-27 | At Loss | 2023-05-19 | At Loss |
| 2023-07-26 | At Loss | 2023-05-18 | At Loss |
| 2023-07-25 | At Loss | 2023-05-17 | At Loss |
| 2023-07-24 | At Loss | 2023-05-16 | At Loss |
| 2023-07-21 | At Loss | 2023-05-15 | At Loss |
| 2023-07-20 | At Loss | 2023-05-12 | At Loss |
| 2023-07-19 | At Loss | 2023-05-11 | At Loss |
| 2023-07-18 | At Loss | 2023-05-10 | At Loss |
| 2023-07-17 | At Loss | 2023-05-09 | At Loss |
| 2023-07-14 | At Loss | 2023-05-08 | At Loss |
| 2023-07-13 | At Loss | 2023-05-05 | At Loss |
| 2023-07-12 | At Loss | 2023-05-04 | At Loss |
| 2023-07-11 | At Loss | 2023-05-03 | At Loss |
| 2023-07-10 | At Loss | 2023-05-02 | At Loss |
| 2023-07-07 | At Loss | 2023-05-01 | At Loss |
| 2023-07-06 | At Loss | 2023-04-28 | At Loss |
Spexis AG (PPHOF) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Spexis AG
ISIN : CH0106213793
Share Class Description:
PPHOF: Registered SharesCompare
Compare
Traded in other countries / regions
SPEX.SwitzerlandSPEXz.UK29Y.GermanyPPHOF.USA IPO Date
2019-10-29Description
Spexis AG is a clinical-stage biopharmaceutical company. The company is engaged in the discovery and development of antibiotics and other specialty pharma products for severe or life-threatening diseases. The company's lead product, murepavadin, is in Phase III development against Pseudomonas aeruginosa - recognized as a critical priority 1 pathogen by World Health Organization. It has one operating segment focusing on the research and development and prospective commercialization of respiratory therapeutics addressing high unmet medical needs.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers